Abstract

Propofol, a widely used intravenous general anesthetic, acts at anesthetic concentrations as a positive allosteric modulator of γ-aminobutyric acid type A receptors and at higher concentration as an inhibitor of nicotinic acetylcholine receptors (nAChRs). Here, we characterize propofol binding sites in a muscle-type nAChR by use of a photoreactive analog of propofol, 2-isopropyl-5-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenol (AziPm). Based upon radioligand binding assays, AziPm stabilized the Torpedo nAChR in the resting state, whereas propofol stabilized the desensitized state. nAChR-rich membranes were photolabeled with [(3)H]AziPm, and labeled amino acids were identified by Edman degradation. [(3)H]AziPm binds at three sites within the nAChR transmembrane domain: (i) an intrasubunit site in the δ subunit helix bundle, photolabeling in the nAChR desensitized state (+agonist) δM2-18' and two residues in δM1 (δPhe-232 and δCys-236); (ii) in the ion channel, photolabeling in the nAChR resting, closed channel state (-agonist) amino acids in the M2 helices (αM2-6', βM2-6' and -13', and δM2-13') that line the channel lumen (with photolabeling reduced by >90% in the desensitized state); and (iii) at the γ-α interface, photolabeling αM2-10'. Propofol enhanced [(3)H]AziPm photolabeling at αM2-10'. Propofol inhibited [(3)H]AziPm photolabeling within the δ subunit helix bundle at lower concentrations (IC50 = 40 μm) than it inhibited ion channel photolabeling (IC50 = 125 μm). These results identify for the first time a single intrasubunit propofol binding site in the nAChR transmembrane domain and suggest that this is the functionally relevant inhibitory binding site.

Highlights

  • Propofol, a general anesthetic, potentiates GABAA receptors and inhibits nicotinic acetylcholine receptors (nAChRs) by binding to unknown sites

  • Based upon radioligand binding assays, AziPm stabilized the Torpedo nAChR in the resting state, whereas propofol stabilized the desensitized state. nAChR-rich membranes were photolabeled with [3H]AziPm, and labeled amino acids were identified by Edman degradation. [3H]AziPm binds at three sites within the nAChR transmembrane domain: (i) an intrasubunit site in the ␦ subunit helix bundle, photolabeling in the nAChR desensitized state (؉agonist) ␦M2-18؅ and two residues in ␦M1 (␦Phe-232 and ␦Cys-236); (ii) in the ion channel, photolabeling in the nAChR resting, closed channel state (؊agonist) amino acids in the M2 helices (␣M2-6؅, ␤M2-6؅ and -13؅, and ␦M2-13؅) that line the channel lumen; and (iii) at the ␥-␣ interface, photolabeling ␣M2-10؅

  • For nAChR-rich membranes in the presence of agonist at equilibrium, Ͼ99% of nAChRs are in the equilibrium desensitized state that binds ACh with highest affinity, whereas in the absence of agonist, ϳ85% of nAChRs are in the resting, closed channel state, and ϳ15% are in the desensitized state [30, 31]

Read more

Summary

Background

A general anesthetic, potentiates GABAA receptors and inhibits nAChRs by binding to unknown sites. Propofol inhibited [3H]AziPm photolabeling within the ␦ subunit helix bundle at lower concentrations (IC50 ‫ ؍‬40 ␮M) than it inhibited ion channel photolabeling (IC50 ‫ ؍‬125 ␮M) These results identify for the first time a single intrasubunit propofol binding site in the nAChR transmembrane domain and suggest that this is the functionally relevant inhibitory binding site. There has been no direct identification of propofol binding sites in a GABAAR or nAChR, within GLIC crystals, Propofol, a potent intravenous general anesthetic, acts as a positive allosteric modulator of inhibitory ␥-aminobutyric acid. Based upon the amino acids photolabeled by [3H]AziPm, we show that it binds to three sites in the nAChR transmembrane domain: within the ␦ subunit helix bundle, in the ion channel, and at the ␥-␣ interface. Propofol acts as an allosteric inhibitor of [3H]AziPm photolabeling in the ion channel and potentiates [3H]AziPm photolabeling at the ␥-␣ interface

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.